4th International Medical Cannabis Conference (CannX 2019) Tel Aviv, Israel, September 9–10, 2019 Abstracts Scientific Committee Dr. Adi Aran Director of the Neuro-Pediatric Unit, Shaare Zedek Medical Center, Israel Prof. Gil Bar-Sela Head, Cancer Center, Emek Medical Center Afula, Israel Dr. Nirit Bernstein Principle Research Scientist, Plant Physiology and Nutrition Institute of Soil Water and Environmental Sciences, Volcani Center, Israel Prof. Lumir Hanus Chief Scientist, Lumir Lab, Associate Professor, Palacký University, Jerusalem Biotechnology Park, Hebrew University, Ein Kerem Campus, Senior Fellow, IEHP, Thomas Jefferson University, Philadelphia, USA, Professor Chaver and Research Fellow, Hebrew University (Ret.) Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University, Israel Dr. Shaul Lev-Ran, MHA Deputy Director, Lev Hasharon Medical Center [...]
Lire la suitePrescription Opioid Distribution after the Legalization of Recreational Marijuana in Colorado Amalie K. Kropp Lopez, Stephanie D. Nichols, Daniel Y. Chung, Daniel E. Kaufman, Kenneth L. McCall and Brian J. Piper International Journal of Environmental Research and Public Health, 2020, 17, 3251 doi : 10.3390/ijerph17093251 Abstract : There have been dynamic changes in prescription opioid use in the US but the state level policy factors contributing to these are incompletely understood. We examined the association between the legalization of recreational marijuana and prescription opioid distribution in Colorado. Utah and Maryland, two states that had not legalized recreational marijuana, were selected for comparison. Prescription data reported to [...]
Lire la suiteEuro consortium will submit consolidated Novel Food application HempToday® May 5, 2020 https://hemptoday.net/euro-novel-food-consortium/ A consortium led by the European Industrial Hemp Association (EIHA), will resort to the current EU food safety approval process for hemp foods and extracts while continuing to challenge those rules.Stakeholders in the consortium, which is being organized as a limited liability company, EIHA projects GmbH, disagree with changes made in January 2019 to the EU’s Novel Food catalogue which re-classified hemp leaves and flowers as well as extracts derived from those plant parts – including CBD – as Novel Foods.But with EU officials and some Member States failing to [...]
Lire la suiteBeneficial Effects of Cannabis on Blood Brain Barrier Function in HIV Ronald J Ellis 1 , Scott Peterson 2 , Mariana Cherner 1 , Erin Morgan 1 , Rachel Schrier 1 , Bin Tang 1 , Martin Hoenigl 1 , Scott Letendre 1 , Jenny Iudicello 1 Clinical infectious diseases, 2020 Apr 16, ciaa437. Doi : 10.1093/cid/ciaa437 Abstract Background: HIV infection leads to blood-brain barrier (BBB) dysfunction that does not resolve despite viral suppression on antiretroviral therapy and is associated with adverse clinical outcomes. In preclinical models, cannabis restores BBB integrity. Methods: We studied people with HIV (PWH) and HIV- individuals who had used cannabis [...]
Lire la suiteIACM-Bulletin, 1 juin 2020 IACM-Bulletin du 01 Juin 2020 Etats-Unis: Les citoyens des États dotés de lois sur le cannabis récréatif considèrent la législation comme un succès Science/Homme: La légalisation de la consommation de cannabis pour les adultes pourrait réduire la consommation d'opioïdes Science/Homme: La consommation de cannabis par les utilisateurs réguliers pourrait n'avoir que des effets minimes sur la cognition IACM-Bulletin du 04 Mai 2020 IACM: Assurer la continuité du traitement pendant la pandémie de COVID-19 pour les patients utilisant du cannabis et des cannabinoïdes. IACM-Bulletin du 02 Mai 2020 Science/Homme: Le cannabis atténue les symptômes de sevrage des [...]
Lire la suiteAstrocytes in rapid ketamine antidepressant action Matjaž Stenovec, Baoman Li, Alexei Verkhratsky, Robert Zorec Neuropharmacology, 2020, 173, 108158 Doi : 10.1016/j.neuropharm.2020.108158 H I G H L I G H T S • Ketamine inhibits calcium signalling and enhances cAMP production in astroglia. • Ketamine suppresses exocytosis of gliosignalling molecules and Kir4.1. • Ketamine elevates cholesterol content in the plasmalemma specifically in astrocytes. A B S T R A C T Ketamine, a general anaesthetic and psychotomimetic drug, exerts rapid, potent and long-lasting antidepressant effect, albeit the cellular and molecular mechanisms of this action are yet to be discovered. Besides targeting neuronal NMDARs fundamental for synaptic transmission, ketamine affects the [...]
Lire la suiteAntidepressant mechanisms of ketamine: Focus on GABAergic inhibition Bernhard Luscher, Mengyang Fenga, Sarah J. Jefferson Advances in Pharmacology, 2020 doi : 10.1016/bs.apha.2020.03.002 Contents 1. Introduction 3 2. Molecular targets of subanesthetic ketamine and its metabolites 6 3. Insights from ketamine indicate a key role for reduced GABAergic inhibition in the pathophysiology of major depression 7 3.1 Antidepressant efficacy of ketamine is controlled by imbalances between neural excitation and inhibition 7 3.2 Chronic imbalances of neural excitation and inhibition lead to homeostatic downregulation of glutamatergic synapses that compromises normal neuronal communication 9 3.3 Chronic imbalances between neural excitation and inhibition lead to defects in GABAergic inhibition that delimit spontaneous recovery from [...]
Lire la suiteExpérimentation de l’usage médical du cannabis : poursuite des travaux - Point d'Information 03/06/2020 Dans la continuité des travaux menés depuis 2018, la Direction générale de la santé (DGS) et l’ANSM restent pleinement engagés dans mise en place de l’expérimentation de l’usage médical du cannabis en France. Cependant, en raison de la nécessaire mobilisation des autorités de santé sur la gestion de l’épidémie de COVID-19, le début de l’expérimentation, initialement prévu en septembre 2020 est reporté au plus tard en janvier 2021. Conduits en concertation avec les membres du Comité scientifique de l’ANSM et les sociétés savantes concernées, les travaux pour la prochaine [...]
Lire la suiteCannabis médical : que penser de la forme de désinvolture de nos «autorités de santé» ? 4 juin 2020 https://jeanyvesnau.com/2020/06/04/cannabis-medical-que-penser-de-la-forme-de-desinvolture-des-autorites-de-sante-francaises/ jeanyvesnau Douleur, Hôpital, Médecine, médicament, Polémique, Politique, Pouvoir, Risques (réduction des), Soigner Bonjour 04/03/2020. Sans doute faudrait-il faire un effort, comprendre les difficultés de l’instant, les agendas perturbés, les responsables trop occupés … On peut, aussi, dire qu’il y a, dans le dernier communiqué de l’Agence nationale de sécurité du médicament (ANSM), sur l’usage médical du cannabis , une forme de désinvolture que l’on peu tenir pour inacceptable vis-à-vis des malades concernés par le sujet. On lit ainsi : « Dans la continuité des travaux menés depuis 2018, [...]
Lire la suiteImpact of COVID-19 on drug services and help-seeking in Europe EMCDDA trendspotter briefing May 2020 The situation regarding public health responses to the COVID-19 pandemic is rapidly evolving. Up-to-date information can be found in the guidelines prepared by national public health sources and the regular updates from the European Centre for Disease Prevention and Control and the World Health Organization. The EMCDDA has created a COVID-19 resource hub for people who use drugs and drug service providers. Summary Since the start of 2020, European countries have been experiencing an unprecedented public health threat with the emergence of the coronavirus disease (COVID-19). In order to investigate [...]
Lire la suite